Envoy Medical (COCH) Q3 2024 earnings summary

Executive summary

• FDA IDE approval received in October 2024 to initiate a pivotal clinical trial for the Acclaim fully implantable cochlear implant, with PMA decision expected in 2027.

• AMA approved new CPT codes for totally implantable middle ear hearing implants, enhancing reimbursement prospects for Esteem FIAMEI.

• Net loss for Q3 2024 was $6.0M, and $16.2M for the nine months ended September 30, 2024; accumulated deficit reached $277.5M.

• Revenue remains minimal, mainly from legacy Esteem FI-AMEI implants and replacements.

• Included in the Russell Microcap Index.

Financial highlights

• Q3 2024 net revenues were $56K, down 30% year-over-year; nine-month revenues were $183K, down 17%.

• Operating loss for Q3 2024 was $5.0M, up 47% year-over-year; nine-month operating loss was $14.7M, up 27%.

• R&D expenses rose to $2.8M in Q3 2024 (up $907K YoY) and $7.7M for nine months (up $1.8M YoY), reflecting increased headcount and clinical trial preparation.

• General and administrative expenses increased 65% in Q3 and 27% for the nine months, driven by public company costs, insurance, and higher legal/professional fees.

• Cash and cash equivalents at September 30, 2024 were $4.4M.

Outlook and guidance

• No material revenue expected until Acclaim CI commercialization; FDA approval targeted for 2026-2027.

• Expenses expected to rise as clinical trials progress and commercialization efforts ramp up.

• Ongoing need for additional capital; substantial doubt exists about ability to continue as a going concern without further funding.

• Plans to advance reimbursement strategy for Esteem FIAMEI and regulatory milestones.